Abstract
Abstract 4965
Soluble interleukin-2-receptor (sIL2R) is a T-cell derived cytokine that induce proliferation of activated T-cells, modulates macrophage function and phenotype and participates in differentiation of B cells. sIL2R levels reflect immune-system activation. and is elevated in HIV-M and may be used to predict esponse to therapy with immunomodulation therapy with BPD.sIL2R has been reported in several malignant diseases with correlation to disease activity. Proinflammatory cytokines IL-6, TNF-alpha, and IL-1b are positively correlated to sIL2R.Plasma cells may produce IL-6 by autocrine mechanism but a paracrine mechanism is involved in IL-6 production in bone marrow stromal cells. Growth of myeloma cells can be induced IL-6. We present a 43 YOF with HIV-M with elevated levels of sIL2R, C-reactive protein (CRP), IgG-kappa,lambda,IgM kappa level with serum free light chain
kappa/lambda ratio. Treatment with biaxin,pentoxifylline, and low dose dexamethasone for 12-24 weeks resulted in normal levels of sIL2R, CRP, IgG,IgM and serum free light chain ratios.
Modulation of sIL2R with BPD in HIV-M patients with elevated proinflammatory cytokines may arrest the disease proliferation by controlling the growth potential IL-6 in both bone marrow plasm cells and peripheral blood mononuclear cells and correlates with the duration of survival.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
